Published in AIDS Weekly, February 19th, 2001
Among those choosing a single PI, 63% selected Viracept (nelfinavir), 18% Crixivan (indinavir), 4% Norvir (ritonavir), 4% Fortovase/Invirase (saquinavir), 1% Kaletra (lopinavir/ritonavir), and 1% Agenerase (amprenavir).
The survey, conducted by Roper Starch Worldwide, Inc., and sponsored by Agouron Pharmaceuticals, comprised 300 physicians who had written at least 22...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.